Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601581 | 0.86 | MAPT (0.47) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL7657674 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6602268 | 0.82 | MAPT (0.49) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6293914 | 0.82 | MAPT (0.68) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6607827 | 0.81 | MAPT (0.38) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL8145894 | 0.81 | MAPT (0.38) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL7951772 | 0.80 | MAPT (0.56) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6298321 | 0.80 | MAPT (0.60) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 | |
| SCHEMBL6601028 | 0.78 | HDAC8 (0.45) | MAPTSMN1; SMN2CYP3A4TP53HDAC8 | |
| SCHEMBL7951754 | 0.78 | MAPT (0.55) | MAPTSMN1; SMN2HSD17B10ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042296-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-25 | — | — | EP | claimed |
| US-6248754-B1 | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2001-06-19 | — | — | US | claimed |
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| EP-1042296-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-6248754-B1 | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2001-06-19 | — | — | US | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1042296-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031068-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | MAPT 4532/4885SMN1; SMN2 4310/4885HSD17B10 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.